According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ NSCLC patients in Beamion Lung-1, with 8% complete responses and 69% partial ...

The Galleri multi-cancer early detection (MCED) test – which looks for around 50 different types – achieved a seven-fold increase in cancer detection when added to standard screening tests for breast, ...

Reimbursement authority NICE has said that Apretude (cabotegravir) can now be used as an alternative to daily oral PrEP pills ...

Millions of women worldwide live with endometriosis, which causes symptoms like pain and extreme tiredness and, if untreated, ...

On Friday 17th October, the European Society for Medical Oncology’s Annual Meeting 2025 kicked off, with the opening press ...

Debruyne has said that in recent years Bavarian Nordic has received several enquiries about a takeover but has never actively ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

Researchers in the UK have started recruiting patients for a large-scale trial that will test a battery of Parkinson's ...

The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher ...

AstraZeneca has become the second pharma group, after Pfizer, to reach an agreement with the Trump administration on a deal ...

Merck KGaA has become the third pharma company to reach an agreement with the Trump administration to cut the cost of some of ...

There is an under-the-radar market access strategy that some manufacturers have implemented, but many others remain unaware ...